BPC-157: A Deep Animal Record, A Thin Human One

The short version

BPC-157 (short for Body Protection Compound 157) is a 15-amino-acid peptide first identified within a protein found in human gastric juice. In animal studies it has shown effects on healing across tendons, ligaments, the gut lining and blood vessels, and it is one of the most talked-about compounds in research-use communities for exactly that reason.

Here is the honest gap: almost all of that evidence comes from rodents. A 2025 review of the literature found only three small pilot studies have ever examined BPC-157 in humans, and rigorous, large-scale human trials are lacking ^[14]. It is not approved as a medicine anywhere in the world, and it is sold only as a research chemical.

This page reports what has actually been studied, in which species, and says plainly where the evidence stops. It never suggests a human dose.

What it is

BPC-157 is a synthetic 15-amino-acid peptide (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val), derived from a partial sequence of a naturally occurring human gastric-juice protein. Its molecular formula is C62H98N16O22. Unlike many peptides, it is described in the literature as notably stable — resistant to breakdown in gastric acid, which is part of why it has drawn interest as an orally active repair compound in animal models, even though the bulk of research uses injectable delivery.

How it works

The best-characterized mechanism for BPC-157 is angiogenic — it promotes the growth of new blood vessels. Specifically, it up-regulates and helps internalize a receptor called VEGFR2 on blood-vessel cells, triggering a downstream signalling cascade that increases nitric oxide production and, in animal and cell studies, increases vessel density and blood-flow recovery in damaged tissue ^[16].

Other proposed mechanisms in the literature include effects on a cell-migration pathway relevant to wound closure, sensitization of growth-hormone signalling in tendon cells, and modulation of the nitric-oxide system and several neurotransmitter pathways. Because nearly all of this mechanistic work comes from animal and cell models, it explains plausible biology rather than confirmed human effects.

What the research shows

The human evidence, such as it is. A first-in-human safety pilot gave intravenous BPC-157, up to 20 mg, to two healthy adults. It was well tolerated, with no adverse events and no measurable changes across cardiac, liver, kidney, thyroid or glucose markers ^[13]. That is the entirety of a controlled human safety signal for this compound — a study of two people. A 2025 narrative review, surveying the whole field, states plainly that only three pilot studies have examined BPC-157 in humans and that rigorous, large-scale trials are lacking, recommending it be treated as investigational ^[14].

Pharmacokinetics — in animals. The first formal characterization of how BPC-157 moves through the body, in rats and beagle dogs, found linear pharmacokinetics, a very short elimination half-life (under 30 minutes), and modest bioavailability by intramuscular injection, with the peptide rapidly broken down into smaller fragments that enter normal amino-acid metabolism ^[15]. No equivalent human pharmacokinetic study exists.

The angiogenesis finding. Across chick membrane models, rat ischemia models and human vascular cells in a dish, BPC-157 consistently increased new blood-vessel formation via the VEGFR2 pathway described above ^[16].

The foundational gastric work. The original cytoprotection studies, in Wistar rats, found BPC-157 reduced gastric ulcer size and sped healing, with injected delivery outperforming oral delivery in that model ^[17].

Reported effects, cautions & safety

Community reports about BPC-157 cluster tightly around tissue repair — anecdotal, not clinical evidence, and never a basis for a dose decision.

Reported benefits: the most common report by a wide margin is faster-feeling recovery from tendon, ligament and joint problems, sometimes within a few weeks. Reduced joint stiffness, improved digestive symptoms, and a general sense of reduced inflammation are also frequently described, along with occasional reports of faster skin healing.

Reported adverse effects: mild injection-site redness or a small bump is the most common complaint, generally described as brief. Nausea or stomach upset, first-week fatigue, headache and transient flushing come up occasionally; palpitations are rarely mentioned but are treated by commentators as a reason to stop and seek medical evaluation.

Cited cautions from the clinical literature:

• The human evidence is extremely thin. As of the most recent reviews, only a handful of small, uncontrolled pilot reports exist in people, and animal findings should not be read as proven human benefits ^[14].
• Much of the foundational literature traces back to one research group, which limits how much independent replication has occurred ^[14].
• It is not an approved drug anywhere, and unregulated research-grade products carry unverified purity and identity ^[14].
• Its strong pro-angiogenic activity is a theoretical concern in active or suspected cancer, since new blood-vessel growth is also how tumours expand — a mechanism-based caution rather than a documented human finding ^[16].
• It is prohibited in competitive sport by anti-doping authorities under their non-approved-substances category, a practical concern for athletes regardless of the medical evidence.
• It has not been studied in pregnancy, breastfeeding or children, and no human data exist to guide use in those groups.

Where it fits in the global research map

BPC-157 illustrates the thinnest end of the evidence spectrum on this desk: an unapproved research chemical with a deep animal literature but only three small human pilot reports on record ^[14]. It shares that unapproved status with MOTS-c, though MOTS-c's human data are observational rather than interventional, while thymosin alpha-1 shows what decades of approved use abroad can build, and semaglutide shows what a full FDA approval pathway produces. Reading BPC-157 against the other three is a useful corrective to the confidence with which it is often discussed online. See the comparison page for the full picture.